novel
avian
influenza
viru
caus
human
infect
china
sinc
isol
fifth
wave
infect
emerg
highli
pathogen
avian
influenza
virus
recombin
hemagglutinin
protein
virus
rapidli
effici
produc
lowlevel
biocontain
facil
studi
recombin
antigen
obtain
engin
stabl
clone
chines
hamster
ovari
cho
cell
subsequ
largescal
product
stabl
cho
cell
clone
also
adapt
grow
serumfre
suspens
cultur
improv
immunogen
recombin
antigen
evalu
use
novel
combin
adjuv
pelc
cpg
pelccpg
augment
immun
respons
mice
compar
effect
adjuv
alum
addavax
sever
tolllik
receptor
ligand
cpg
poli
c
pelccpg
combin
adjuv
cho
cellexpress
antigen
contain
termin
sialyl
complex
type
nglycan
abl
induc
high
titer
neutral
antibodi
sera
confer
protect
follow
live
viru
challeng
data
indic
cho
cellexpress
recombin
antigen
pelccpg
combin
adjuv
use
subunit
vaccin
develop
influenza
virus
negativesens
rna
virus
belong
orthomyxovirida
famili
hemagglutinin
ha
neuraminidas
na
two
major
viral
envelop
protein
gener
use
classifi
differ
influenza
serotyp
differ
type
ha
na
respect
novel
avian
influenza
viru
isol
china
outbreak
alreadi
caus
five
wave
human
infect
fifth
epidem
wave
sever
confirm
human
case
probabl
due
geograph
spread
viru
eastern
china
throughout
whole
countri
importantli
virus
isol
fifth
epidem
wave
evolv
two
distinct
lineag
name
yangtz
river
delta
pearl
river
delta
lineag
fifthepidemicwav
isol
yangtz
river
delta
lineag
carri
polybas
amino
acid
cleavag
site
characterist
highli
pathogen
avian
influenza
virus
recent
evid
indic
vaccin
strain
may
elicit
crossreact
immun
respons
toward
recent
isol
world
health
organ
suggest
two
addit
candid
vaccin
strain
ahong
besid
two
previou
vaccin
strain
http
www
whointinfluenzavaccinesviruscandidatesreagentssummari
ua
develop
effect
vaccin
best
way
prevent
spread
viru
curtail
potenti
pandem
inactiv
split
vaccin
requir
variou
adjuv
system
includ
alum
adjuv
adjuv
iti
prepar
inactiv
split
vaccin
essenti
carri
biosafeti
level
facil
eggbas
cell
culturebas
viru
propag
inactiv
purif
process
recombin
subunit
vaccin
rapidli
effici
produc
requir
lowlevel
biocontain
vaccin
manufactur
recombin
antigen
success
express
e
coli
insect
cell
mammalian
cell
howev
antigen
need
adjuv
formul
boost
immun
report
ligand
flagellin
polyethylenimin
poli
c
alum
squalenebas
oilinwat
emuls
system
antigen
structur
influenza
ha
protein
complex
requir
extens
nlink
glycosyl
maintain
immunogen
one
approach
obtain
engin
stabl
clone
chines
hamster
ovari
cho
cell
longterm
express
recombin
ha
antigen
cultur
supernat
product
method
may
allow
semicontinu
continu
harvest
recombin
glycoprotein
within
extend
period
time
therebi
provid
advantag
develop
costeffect
industri
process
use
cho
cell
technolog
recent
obtain
highyield
produc
stabl
cell
clone
product
glycanmask
vaccin
similar
strategi
also
report
product
homogen
envelop
sosip
trimer
vaccin
merscoronaviru
vaccin
antigen
studi
express
antigen
engin
stabl
clone
cho
cell
singl
cell
clone
standard
dhfrmethotrex
mtx
gene
amplif
select
procedur
screen
evalu
immunogen
formul
differ
adjuv
system
mice
antibodi
respons
analyz
determin
titer
igg
igg
subtyp
hemagglutin
inhibit
hi
microneutr
mn
sera
protect
immun
also
assess
follow
live
viru
challeng
find
indic
formul
pelccpg
combin
adjuv
use
subunit
vaccin
develop
code
sequenc
protein
carri
ectodomain
ha
sequenc
trimer
motif
histidin
tag
gene
clone
express
vector
contain
pcmv
promot
iv
intern
ribosom
entri
site
ire
driven
dihydrofol
reductas
dhfr
zeocin
resist
gene
obtain
highyield
stabl
clone
cho
cell
previous
describ
cho
dhfr
dhfr
defici
cell
atcc
bioresourc
collect
research
center
taiwan
maintain
minimum
essenti
medium
alpha
medium
mema
ribonucleosid
deoxyribonucleosid
invitrogen
supplement
fetal
bovin
serum
amplifi
cho
cell
select
perform
mema
supplement
dialyz
fetal
bovin
serum
invitrogen
without
rn
drn
express
vector
transfect
chodhfrcel
use
lipofectamin
invitrogen
establish
perman
clone
h
posttransfect
cell
plate
subcultur
duplic
well
plate
medium
well
replac
mema
without
rn
drn
supplement
dialyz
fetal
bovin
serum
invitrogen
lgml
zeocin
invitrogen
follow
week
select
remain
cell
dilut
inocul
plate
singl
clone
select
week
incub
singl
cell
clone
select
visual
inspect
microscopi
addit
cell
clone
select
perform
gradual
increas
concentr
mtx
sigma
inhibitor
dhfr
protein
lm
select
concentr
occur
week
period
cell
clone
surviv
follow
treatment
mm
mtx
collect
analyz
western
blot
use
antibodi
genetex
inc
confirm
express
final
select
clone
cultur
cultur
supernat
harvest
purif
use
nickelchel
resin
affin
chromatographi
tosoh
previous
describ
purifi
protein
treat
endoglycosidas
h
endo
h
new
england
biolab
nglycosidas
f
pngase
f
new
england
biolab
western
blot
character
obtain
highmannos
mannosetermin
type
nglycan
also
grew
stabl
cho
cell
clone
medium
contain
lm
kifunensin
kif
mannosidas
inhibitor
capabl
block
highmannos
trim
process
complex
type
nglycan
biosynthesi
procedur
previous
report
obtain
singlenacetylglucosamin
glcnac
type
nglycan
purifi
protein
obtain
form
kiftreat
cho
cell
cultur
react
endo
h
new
england
biolab
h
endo
h
use
cleav
high
mannos
hybrid
oligosaccharid
nlink
glycoprotein
within
chitobios
core
femal
balbc
mice
week
old
mice
per
group
intramuscularli
immun
twice
interv
group
mice
immun
phosphatebuff
salin
pb
lg
protein
without
lg
alum
adjuv
adjupho
brenntag
lg
invivogen
lg
cpg
oligodeoxynucleotid
addavax
invivogen
lg
poli
c
invivogen
pelccpg
pelc
lg
cpg
procedur
involv
anim
perform
accord
guidelin
establish
laboratori
anim
center
nation
tsing
hua
univers
nthu
anim
protocol
review
approv
nthu
institut
anim
care
use
committe
plate
coat
mg
protein
overnight
block
pb
buffer
contain
bsa
serum
sampl
twofold
serial
dilut
incub
h
room
temperatur
plate
subsequ
incub
ml
hrpconjug
antimous
igg
igg
subtyp
antibodi
follow
treatment
ml
tmb
substrat
biolegend
reaction
stop
addit
n
h
optic
densiti
nm
measur
tecan
spectrophotomet
hi
assay
serum
sampl
overnight
treat
receptordestroy
enzym
denka
seiken
twofold
serial
dilut
incub
four
ha
unit
viru
turkey
rbc
ad
treat
serum
sampl
hi
titer
determin
reciproc
highest
dilut
could
complet
inhibit
hemagglutin
mn
assay
serum
sampl
serial
dilut
twofold
coincub
equal
volum
viru
diluent
h
incub
prepar
mdck
cell
infect
determin
detect
cytopath
effect
day
neutral
titer
defin
reciproc
highest
serum
dilut
could
neutral
viru
infect
infect
cell
compar
uninfect
cell
three
week
final
immun
mice
anesthet
intranas
challeng
viru
volum
mous
surviv
weight
loss
monitor
daili
day
per
institut
anim
care
use
committe
iacuc
guidelin
bodi
weight
loss
serv
endpoint
mous
challeng
experi
evalu
approv
iacuc
academia
sinica
surviv
mice
immun
experi
sacrif
use
carbon
dioxid
accord
isciii
iacuc
guidelin
cho
cell
clone
adapt
mema
medium
gibco
supplement
fetal
bovin
serum
biolog
industri
serumfre
balancd
cho
growth
medium
irvinescientif
contain
glutamax
gibco
flask
cho
cell
clone
adapt
serumfre
medium
gradual
decreas
volum
serumcontain
medium
increas
volum
serumfre
medium
cell
detach
flask
suspend
serumfre
medium
cell
transfer
ml
spinner
flask
cultur
rpm
work
volum
ml
medium
replac
fresh
medium
everi
day
suspend
cell
count
use
hemocytomet
cell
count
day
cultur
determin
plot
cell
growth
curv
concentr
serumfre
cell
cultur
supernat
measur
elisa
use
influenza
hemagglutininha
elisa
pair
set
kit
sino
biolog
describ
manufactur
protocol
brief
plate
coat
ml
captur
antibodi
mg
ml
pb
overnight
three
time
wash
tbst
mm
tri
mm
nacl
well
block
h
tbst
contain
bsa
total
ml
cultur
supernat
sampl
collect
day
ad
individu
well
incub
h
three
wash
ml
hrpconjug
detect
antibodi
mgml
tbst
bsa
ad
plate
incub
h
three
wash
tmb
substrat
ad
well
develop
reaction
n
h
use
eventu
stop
reaction
absorb
nm
wavelength
record
fit
standard
curv
protein
measur
protein
concentr
result
analyz
oneway
anova
tukey
test
graphpad
prism
valu
p
indic
statist
signific
experi
perform
least
twice
gene
encod
ha
viru
strain
addit
sequenc
histidin
tag
clone
express
vector
contain
pcmv
promot
iv
iresdriven
dhfr
zeocinresist
gene
fig
dhfrdefici
cho
cell
chodhfr
transfect
plasmid
posit
transform
select
zeocin
singl
cell
clone
dhfr
mtxstepwis
select
perform
obtain
stabl
clone
stepwis
increas
mtx
select
procedur
surviv
clone
mm
mtx
maintain
least
five
passag
ensur
stabil
express
protein
purifi
cell
cultur
supernat
nickel
affin
chromatographi
result
sdspage
coomassi
brilliant
blue
stain
show
molecular
mass
kda
fig
nglycan
pattern
protein
predominantli
complex
type
owe
resist
endo
h
pngase
evid
western
blot
result
fig
addit
alreadi
report
nglycan
profil
use
hydrophil
interact
liquid
chromatographyhighperform
liquid
chromatographi
major
glycoform
contain
triand
tetraantennari
structur
one
termin
sialic
acid
sia
gal
man
glcnac
fuc
sia
gal
man
glcnac
fuc
group
balbc
mice
intramuscularli
immun
mg
mg
formul
alum
cpg
addavax
poli
c
pelccpg
adjuv
within
period
fig
antisera
collect
week
second
dose
immun
mg
dose
total
igg
antibodi
titer
significantli
higher
pelccpg
adjuv
adjuv
fig
furthermor
mg
dose
addavax
poli
c
pelccpg
adjuv
show
slightli
higher
igg
titer
titer
observ
differ
statist
signific
fig
therefor
formul
contain
combin
pelccpg
trigger
strongest
igg
respons
titer
subtyp
induc
pelccpg
adjuv
significantli
higher
induc
alum
cpg
addavax
poli
c
adjuv
mg
dose
fig
furthermor
pelc
cpg
poli
c
adjuv
yield
higher
titer
alum
cpg
adjuv
fig
e
result
also
show
mg
dose
formul
pelccpg
adjuv
significantli
higher
titer
induc
alum
cpg
addavax
poli
c
adjuv
fig
f
sinc
known
drive
induct
secret
adjuv
pelccpg
appear
enhanc
cellular
respons
use
pelccpg
adjuv
also
result
higher
titer
capabl
activ
fc
effector
function
antibodydepend
cellular
cytotox
antisera
also
analyz
titer
hi
mn
antibodi
mg
use
alum
pelccpg
adjuv
higher
hi
titer
compar
without
adjuv
use
use
cpg
addavax
poli
c
adjuv
fig
mg
hi
titer
significantli
higher
pelccpg
alum
cpg
adjuv
fig
evalu
titer
mn
antisera
found
highest
titer
report
presenc
pelccpg
adjuv
adjuv
dose
mg
fig
therefor
use
pelccpg
adjuv
clearli
improv
titer
hi
mn
antibodi
alum
adjuv
immun
mice
analyz
protect
immun
group
mice
immun
mg
mg
combin
pelc
cpg
treat
pbscontrol
group
challeng
ld
viru
surviv
rate
slightli
decreas
dose
lower
mg
pelccpg
adjuv
fig
bodi
weight
loss
also
increas
dose
reduc
mg
pelccpg
adjuv
howev
formul
use
mediat
complet
recoveri
fig
observ
indic
immun
mg
mg
sinc
cho
cellexpress
recombin
antigen
contain
termin
sialyl
complex
type
nglycan
also
obtain
two
type
differ
nglycan
pattern
kif
high
mannosetyp
mannosetermin
nglycan
use
kif
treatment
ii
kif
e
singl
glcnactyp
nglycan
use
kif
treatment
endo
h
digest
previous
report
observ
gradual
reduc
molecular
weight
kif
kif
e
sdspage
gel
stain
commassi
blue
fig
group
balbc
mice
immun
mg
kif
kif
e
pelccpg
adjuv
follow
immun
viru
challeng
regimen
result
indic
reduc
mn
titer
dose
kif
larger
degre
kif
e
compar
immun
fig
follow
live
viru
challeng
immun
plu
pelccpg
result
protect
surviv
rate
full
bodi
weight
recoveri
fig
protect
observ
immun
either
mg
kif
mg
kif
e
formul
pelccpg
adjuv
fig
therefor
termin
sialyl
complex
type
nglycan
provid
protect
live
viru
challeng
meet
requir
industri
applic
stabl
cho
cell
clone
adapt
serumfre
condit
gradual
decreas
fb
content
medium
eventu
adapt
cho
cell
clone
cultur
singl
cell
suspens
serumfre
medium
spinner
flask
cell
growth
product
monitor
day
cultur
medium
complet
replac
fresh
medium
day
maintain
cell
viabil
around
fig
result
cell
densiti
increas
cellsml
day
cellsml
day
fig
cell
viabil
adapt
cell
clone
serumfre
suspens
cultur
howev
cell
growth
slow
doubl
time
around
day
titer
product
cultur
supernat
increas
mgl
day
mgl
day
day
fig
final
yield
product
mgl
approxim
doubl
amount
adher
cell
serumcontain
cultur
result
indic
cho
cell
clone
adapt
grow
serumfre
suspens
cell
cultur
report
success
obtain
engin
stabl
clone
cho
cell
product
antigen
may
use
develop
recombin
ha
vaccin
stabl
clone
success
adapt
grow
well
serumfre
suspens
cultur
properti
may
allow
largescal
product
clone
yield
produc
engin
stabl
cell
clone
approxim
twice
amount
obtain
serumcontain
adher
cultur
improv
cho
cell
cultur
process
via
medium
optim
fedbatch
cultiv
extend
cultur
period
may
increas
yield
antigen
product
milligram
gram
per
liter
report
envelop
antigen
product
stabl
cho
cell
evalu
abil
pelccpg
combin
adjuv
augment
immunogen
mice
nonpathogenassoci
molecular
pattern
nonpamp
adjuv
alum
addavax
pamp
adjuv
like
tolllik
receptor
tlr
ligand
cpg
poli
c
use
adjuv
parallel
comparison
pelc
addavax
adjuv
formul
use
squalenebas
oilinwat
emuls
similar
composit
adjuv
squalen
tween
citrat
buffer
pelc
formul
one
differ
composit
obtain
replac
tween
biodegrad
poli
ethylen
glycol
b
lockpoli
lactidecoecaprolacton
pegbplacl
polym
compar
addavax
adjuv
effect
adjuv
augment
immunogen
compar
alum
adjuv
known
caus
cell
death
releas
numer
molecul
act
damageassoci
molecular
pattern
damp
alert
innat
immun
system
alum
also
activ
inflammasom
induct
effect
bcell
respons
bias
cellular
immun
respons
addavax
like
potent
adjuv
elicit
broader
immun
respons
alum
adjuv
studi
show
combin
pelccpg
adjuv
elicit
significantli
higher
titer
igg
antibodi
hiand
mnneutral
antibodi
mice
alum
addavax
sever
tlr
ligand
investig
c
surviv
rate
bodi
weight
loss
immun
mice
follow
live
viru
challeng
monitor
day
mice
whose
bodi
weight
fell
initi
weight
sacrif
fig
stabl
cho
cell
clone
serumfre
suspens
cultur
cell
densiti
product
titer
adapt
stabl
cho
cell
clone
cultur
serumfre
suspens
cultur
cultur
medium
complet
replac
fresh
medium
day
maintain
cell
viabil
around
studi
result
concord
report
studi
inactiv
vaccin
pelccpg
combin
adjuv
trival
influenza
vaccin
combin
alum
calcium
phosphat
poli
lactid
coglycolid
cpg
adjuv
act
synergist
elicit
antiinfluenza
immun
antigen
properti
influenza
ha
includ
bind
rbc
agglutin
well
sialic
acid
present
bovin
fetuin
glycoprotein
previous
report
antigen
lost
abil
agglutin
turkey
rbc
well
bind
sialic
acidscontain
bovin
fetuin
glycprotein
wherea
insect
cellderiv
antigen
retain
properti
although
antigen
unabl
agglutin
rbc
bind
sialic
acidscontain
fetuin
data
establish
present
studi
clearli
demonstr
antigen
immunogen
induc
immun
respons
mice
also
obtain
two
nglycan
type
antigen
kif
high
mannosetyp
nglycan
ii
kif
e
singl
glcnactyp
nglycan
kif
e
antigen
kif
antigen
abl
regain
weak
properti
rbc
agglutin
data
shown
pelccpg
combin
adjuv
mg
dose
kif
kif
e
elicit
protect
respons
confer
protect
surviv
bodi
weight
recoveri
immun
mice
follow
live
viru
challeng
result
contradictori
antigen
produc
cho
cell
limit
nlink
glycosyl
earli
oligomannos
glycan
enhanc
subunit
vaccin
efficaci
present
result
demonstr
cho
cellexpress
antigen
contain
termin
sialyl
complex
type
nglycan
high
mannosetyp
singl
glcnactyp
nglycan
provid
protect
infect
furthermor
previous
report
antigen
remov
termin
sialic
acid
moieti
improv
immun
compar
nlink
complex
type
antigen
paucimannosetyp
cellderiv
antigen
ongo
studi
investig
antigen
remov
sialic
acid
moieti
may
improv
immun
conclus
present
studi
demonstr
new
method
product
vaccin
use
engin
stabl
clone
cho
cell
clone
express
antigen
adapt
grow
serumfre
suspens
cultur
may
use
largescal
industri
product
subunit
vaccin
pelccpg
combin
adjuv
cho
cellexpress
antigen
contain
termin
sialyl
complex
type
nglycan
abl
induc
high
titer
neutral
antibodi
sera
confer
protect
follow
live
viru
challeng
data
indic
antigen
coupl
pelccpg
combin
adjuv
formul
may
use
develop
effect
subunit
vaccin
